Novartis Extends Tender Offer for Eon Labs, Inc. Through July 1, 2005
21 juin 2005 07h00 HE
|
Novartis
BASEL, Switzerland, June 21, 2005 (PRIMEZONE) -- Novartis announced today that Zodnas Acquisition Corp., an indirect wholly owned subsidiary of Novartis, is extending its cash tender offer to acquire...
Novartis Announces Completion of Hexal AG Acquisition, Integrates Company With Sandoz
07 juin 2005 01h31 HE
|
Novartis
BASEL, Switzerland, June 7, 2005 (PRIMEZONE) -- Novartis (NYSE:NVS) announced today the completion of its acquisition of the generic pharmaceutical company Hexal AG in Germany on June 6. The...
Novartis Highlights Pharmaceutical Research Strategy, Intensifying Focus on Molecular Pathways Shared by Various Diseases
03 mai 2005 01h30 HE
|
Novartis
-- Transforming the "grammar" of drug discovery by focusing on
molecular pathways and patient stratification
-- Redefining Research-to-Development transition through fast and
rigorous...
Novartis Files Exjade New Drug Applications for Treatment of Chronic Iron Overload Due to Blood Transfusions
03 mai 2005 01h30 HE
|
Novartis
-- Innovative, once-a-day oral formulation offers life-altering
treatment option to broad range of iron overload patients
-- Filings based on data from largest prospective clinical trials
...
Novartis: New Study Finds Coartem (Artemether-Lumefantrine) is the Most Effective Malaria Treatment in Areas of High Resistance to Conventional Anti-Malarials
26 avr. 2005 11h57 HE
|
Novartis
- USD170 million financing commitment from Global Fund
will help secure the majority of 2005-2006 Coartem supply
- Novartis continues unprecedented production scale-up to
meet rapidly...
Novartis Continues to Outpace The Market, Delivering Strong First Quarter 2005 Sales and Earnings Growth
21 avr. 2005 01h15 HE
|
Novartis
BASEL, Switzerland, April 21, 2005 (PRIMEZONE) -- Novartis (NYSE:NVS): Key figures
First quarter
Q1 2005 Q1 2004 % Change
...
Novartis: PTK/ZK CONFIRM 1 Study Shows Positive Drug Effects in Phase III Study in Metastatic Colorectal Cancer, Filing Now Anticipated for Early 2007
21 mars 2005 00h13 HE
|
Novartis
Pre-planned analysis of progression-free survival as assessed by
investigators achieved statistical significance while analysis of
primary endpoint of progression-free survival assessed by...
Novartis to Acquire Hexal AG and Eon Labs, Creating the World Leader
21 févr. 2005 01h30 HE
|
Novartis
-- Significantly broadened product portfolio
-- One of the largest pipelines in industry covering most generic
opportunities
-- Best-in-class development teams with proven record of being...
Novartis Obtains Rights from Otsuka to Develop New Treatment for Dry Eye
07 févr. 2005 01h30 HE
|
Novartis
-- Novel mechanism of action expected to enhance tear secretion and
increase mucin levels covering conjunctiva and cornea
-- Over 22 million patients visit ophthalmologists each year seeking...
Novartis Delivers Record Results With Strong Double-Digit Net Sales And Earnings Growth In 2004
20 janv. 2005 01h22 HE
|
Novartis
BASEL, Switzerland, Jan. 20, 2005 (PRIMEZONE) --Novartis (NYSE:NVS): Pharmaceuticals, led by the innovative, fast-growing oncology and cardiology franchises, drives expansion with market share...